149 related articles for article (PubMed ID: 37596405)
1. Histopathology and levels of proteins in plasma associate with survival after colorectal cancer diagnosis.
Magnusson MI; Agnarsson BA; Jonasson JG; Tryggvason T; Aeffner F; le Roux L; Magnusdottir DN; Gunnarsdottir HS; Alexíusdóttir KK; Gunnarsdottir K; Söebech E; Runarsdottir H; Jonsdottir EM; Kristinsdottir BS; Olafsson S; Knutsdottir H; Thorsteinsdottir U; Ulfarsson MO; Gudbjartsson DF; Saemundsdottir J; Magnusson OT; Norddahl GL; Watson JEV; Rafnar T; Lund SH; Stefansson K
Br J Cancer; 2023 Oct; 129(7):1142-1151. PubMed ID: 37596405
[TBL] [Abstract][Full Text] [Related]
2. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.
Samadder NJ; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
Gastroenterology; 2013 Aug; 145(2):348-56.e1-2. PubMed ID: 23665275
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
[TBL] [Abstract][Full Text] [Related]
5. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
[TBL] [Abstract][Full Text] [Related]
7. High-frequency microsatellite instability and BRAF mutation (V600E) in unselected Serbian patients with colorectal cancer.
Markovic S; Antic J; Dragicevic N; Hamelin R; Krivokapic Z
J Mol Histol; 2012 Apr; 43(2):137-43. PubMed ID: 22210186
[TBL] [Abstract][Full Text] [Related]
8. Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer.
Kang M; Shen XJ; Kim S; Araujo-Perez F; Galanko JA; Martin CF; Sandler RS; Keku TO
Cancer Biomark; 2013; 13(5):359-66. PubMed ID: 24440976
[TBL] [Abstract][Full Text] [Related]
9. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
Goldstein J; Tran B; Ensor J; Gibbs P; Wong HL; Wong SF; Vilar E; Tie J; Broaddus R; Kopetz S; Desai J; Overman MJ
Ann Oncol; 2014 May; 25(5):1032-8. PubMed ID: 24585723
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
11. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
[TBL] [Abstract][Full Text] [Related]
12. External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS.
Alwers E; Bläker H; Walter V; Jansen L; Kloor M; Arnold A; Sieber-Frank J; Herpel E; Tagscherer KE; Roth W; Chang-Claude J; Brenner H; Hoffmeister M
BMC Cancer; 2019 Jul; 19(1):681. PubMed ID: 31296182
[TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
[TBL] [Abstract][Full Text] [Related]
14. The prognostic and predictive impact of
Park R; Lopes L; Lee S; Riano I; Saeed A
Future Oncol; 2021 Nov; 17(31):4221-4231. PubMed ID: 34323124
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics.
Phipps AI; Buchanan DD; Makar KW; Burnett-Hartman AN; Coghill AE; Passarelli MN; Baron JA; Ahnen DJ; Win AK; Potter JD; Newcomb PA
Cancer Epidemiol Biomarkers Prev; 2012 Oct; 21(10):1792-8. PubMed ID: 22899730
[TBL] [Abstract][Full Text] [Related]
16. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
19. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
[TBL] [Abstract][Full Text] [Related]
20. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
